

**AAO23: Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines**

**High Priority:** No; N/A

Percentage of patients age 2 years and older with allergic rhinitis who are offered intranasal corticosteroids (INS) or non-sedating oral antihistamines.

**Denominator:**

All patients age 2 years and older with a diagnosis of allergic rhinitis.

**Denominator Exclusions:**

None

**Denominator Exceptions:**

Patients with an allergy to oral antihistamines or intranasal corticosteroids.

Patients with prostate cancer or benign prostatic hypertrophy as these patients may be intolerant of medications.

Patients with a history of epistaxis due to intranasal steroids use.

Patient refusal.

**Numerator:**

Patients who are taking intranasal steroids (INS) or non-sedating oral antihistamines. A prescription for or medication reconciliation of over the counter medications can be used to identify patients taking medications.

**Measure Classifications:**

Measure Type: Process

National Quality Strategy (NQS) domain: Effective Clinical Care

Meaningful Measure Area: Medication Management

Calculation: 1st Performance Rate

Inverse measure: No

Continuous measure: No

Proportional measure: Yes

Ratio measure: No

Risk Adjusted measure: No

© 2020 American Academy of Otolaryngology–Head and Neck Surgery Foundation. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g. use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF).

Disclaimer: The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Neither the AAO-HNSF nor its members shall be responsible for any use of the Measures. The AAO-HNSF and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.


# AAO23

## Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines


### INITIAL PATIENT POPULATION (IPP)

**MEASURE DESCRIPTION**

Percentage of patients with allergic rhinitis who are offered intranasal corticosteroids (INS) or non-sedating oral antihistamines.



### DENOMINATOR



### NUMERATOR

